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Abstract: Several studies have underlined the interplay among host-microbiome and pathophysiological
conditions of animals. Research has also focused specifically on whether and how changes in the
gut microbiome have provoked the occurrence of pathological phenomena affecting cartilage and
joints in humans and in laboratory animals. Here, we tried to evaluate the relationship between
the gut microbiome and the hip and elbow arthritis in owned dogs. The study included 14 dogs
suffering from chronic arthritis (AD) and 13 healthy dogs (HD). After the first visit and during
the period of the study, the dogs, under the supervision of the owner, were fed a semi-moist
complete diet supplemented with omega 3 fatty acids. Feces and blood samples were collected
in the clinic at the first visit (T0) and after days (T45). The plasma C-reactive protein (CRP) was
higher, and the serum vitamin B12 and folate concentrations were lower (p < 0.05) in the AD
group in comparison to the HD group. Data of the fecal microbiome showed that the relative
abundances of the genus Megamonas were higher in AD (p < 0.001), while the relative abundance
of the families Paraprevotellaceae, Porphyromonadaceae, and Mogibacteriaceae was significantly
lower in comparison to HD. The results of the study identified several bacterial groups that differed
significantly in the fecal microbiome between healthy and diseased dogs. If the observed differences
in fecal bacterial composition predispose dogs to hip and elbow arthritis or if these differences reflect
a correlation with these conditions deserves further investigation.
Keywords: gut microbiome; hematological parameters; arthritis; dogs
1. Introduction
In the last decade, several studies have focused on the gut microbiome in dogs and on the
relationship that inflammatory bowel diseases and intestinal dysbiosis have with pathological
conditions of the organism [1,2]. It has been also demonstrated, both in human and animal models,
that the microorganism inhabitants of the gut and the compounds they produce, such as short-chain
fatty acids, lactic acid, and metabolites of amino acids, affect host physiology [3]. Among the others,
the microbial metabolism of tryptophan and threonine and the related interaction with the availability of
neurotransmitters for the host has led to the development of the brain-gut-microbiome axis concept [4,5].
It has also been reported that the microbiome can influence distant organs by three principal effects,
regulating the nutritional absorption and production of vitamins, regulating the immune system, and
translocating bacteria through the endothelial barrier and into the bloodstream [6]. This has been
investigated in human and laboratory animals [7–10], but scientific pieces of evidence are still lacking
for dogs.
Recent studies have brought to light a possible new interplay of the gut microbiome with
pathological conditions other than inflammatory bowel diseases, such as metabolic syndrome and joint
damage, the latter caused by chronic low-grade systemic inflammation [3]. It is already accepted that
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when intestinal dysbiosis occurs, the whole organism suffers from several metabolic and inflammatory
diseases, and in this context, it is conceivable to assume that also the pathogenesis of the joint disease
could be related to it.
According to Tomasello et al. (2014) [11], in humans affected by irritable bowel syndrome,
it was observed that during microbial dysbiosis, an immune system dysregulation could occur, which
consequently brought to a local inflammatory state. Hernandez et al. (2018) [6] reported that during
dysbiosis, a leaky gut could happen, and this allowed a transfer of gut microbes from the intestinal
lumen to other sites of the body (e.g., mammary gland; [12]) through dendritic cells (DCs) and
macrophages. If this crossing is implicated in the onset of joint disease is a hypothesis that deserves
further investigation.
Osteoarthritis is a chronic disease that in the long run leads to a degradation of cartilage and bone,
abnormal growth of bone tissue (osteophytes), and inflammation of the synovial membrane (synovitis),
causing arthrosis and pain, stiffness, and loss of functionality of the joints [13–15]. This pathology is
multifactorial and is mainly related to genetic predisposition, mechanical events, age, sex, lifestyle,
poor body condition, and excess body weight [3].
A common feature of arthrosis is local and sometimes systemic inflammation, but, until now,
the gut-joint axis has only been hypothesized in human and laboratory animals [9–16], considering
that clinical evidence linking gut microbiome with arthritis is still lacking. In this study, we evaluated
hematological parameters, fecal microbiome composition, and end products of fermentation in healthy
and arthritic dogs with the aim to evaluate a relationship, if any, supporting the microbiome-joint axis
in dogs.
2. Materials and Methods
2.1. Animals and Housing
For the purpose of the study, 13 healthy dogs (HD) and 14 dogs with hip or elbow arthritis
(AD) were enrolled from a veterinary local clinic. AD dogs had a history of chronic arthritis and
were not under NSAIDs (non-steroidal anti-inflammatory drugs) or steroidal treatments since the last
month. Arthritis was diagnosed by the veterinarians on the basis of clinical anamnesis for limping
forelimbs and/or associated with posterior limping; rapid fatigue after effort; decrease in motor activity;
radiographic evidence of osteoarthritis (AD) in one or two joints (elbow, hips). Dogs were of both
sex and different breeds, including crossbreeds, were older than 18 months, and weighed more than
10 kg and less than 40 kg. Details of the dogs are reported in Supplementary Table S1. After the
visit, HD and AD dogs were fed a semi-moist complete diet (N.P. Industries, Udine, Italy). The diet
consisted of the diced potato (4.0%), potato starch (4.0%), chicken (17.8%), swine heart (17.0%), swine
lung (10.0%), swine liver (7.4%), vitamins and minerals (1.25%), additives (thickeners, gelling agents;
1.8%), vegetable oil (1.25%), prebiotic (xylooligosaccharides, 0.01%), and oregano essential oil (0.0006%).
Diet contained 80.0% of water, 7.2% of crude protein, 5.4% of lipids, 0.45% of crude fiber, 2.1% of
ash, and 3.3% of starch. Lipids contained 5.3% of omega 3 (alpha-linolenic 3.7%, eicosapentaenoic
0.5%, and docosahexaenoic 0.3%). The diet was formulated to provide omega 3 fatty acids to support
the metabolism of joints in the case of osteoarthritis. Throughout the period of study, dogs were
housed in the usual home and condition and were followed by the owners, and informed consent was
obtained from the owners of the dogs recruited for the study. All protocols, procedures, and the care of
the animals complied with the Italian legislation on animal care and were approved by the ethical
committee of the University of Udine (26/08/2019; protocol n. 7/2019).
2.2. Collection of Samples
The samples from HD were collected according to a scheduled check agreed with the owners, and
for the AD, the samples were collected according to the veterinary opinion to monitor their clinical
conditions. Blood samples were withdrawn at the first clinical examination (T0) and after 45 days (T45)
Vet. Sci. 2020, 7, 92 3 of 16
from the beginning of the trial in the veterinary clinic. Fecal samples were also collected at T0 and T45
from the first evacuation of the morning by the owners, and the specimens were immediately frozen
at −20 ◦C. Samples were delivered to the clinic and transported to the laboratory within 1 week and
stored at −80 ◦C. For the analyses, the inner part of the stools was sampled for analysis.
2.3. Hematological Analysis
Blood samples were collected at the veterinary clinic in Li-heparin tubes (Terumo Europe N.V.,
Leuven, Belgium) and without anticoagulant tubes and then centrifuged at 3000 RPM for 20 min.
Plasma and serum were transferred in 5 mL vials and immediately frozen at −20 ◦C. The samples were
sent within 3 days to an external certified veterinary laboratory for a complete biochemical analysis of
plasma, folate, vitamin B12, and trypsin-like immunoreactivity (TLI) in serum (Vetlab, Padova, Italy).
2.4. Fecal Short-Chain Fatty Acid and Lactic Acid Analysis
Lactic acid and short-chain fatty acids (SCFAs) (acetic, propionic, butyric, isobutyric, and isovaleric)
were analyzed by HPLC [17], starting from 1 g of feces, which was diluted with 50 mL of 0.1 N H2SO4
aqueous solution and homogenized for 15 min by a mechanical stirrer (Instruments Srl, Milano, Italy).
After centrifugation at 20,000× g for 20 min at 4 ◦C to separate the liquid phase from the solid residuals,
the supernatant was filtered with a 0.45 µm syringe filter of polypore (Alltech, Casalecchio di Reno,
BO, Italy). An aliquot of 20 µL of the resulting sample was injected in the HPLC equipped with an
Aminex HPX-87H (Bio-Rad, Hercules, CA, USA) ion exclusion column (300 mm × 7.8 mm, 9 µm) and
a pre-column (Bio-Rad, Hercules, CA, USA) kept at 40 ◦C. The isocratic elution flux was 0.6 mL/min,
using 0.008 N H2SO4 solution as a mobile phase, and the detection length was 220 nm. SCFAs and
lactic acid concentrations were calculated with reference to a standard solution of 4.50 mg/mL of
lactic acid, 5.40 mg/mL of acetic acid, 5.76 mg/mL of propionic acid, 7.02 mg/mL of butyric acid and
isobutyric acid and isovaleric acid in 0.1N H2SO4 (Sigma–Aldrich® Co., Milano, Italy). Quantifications
were calculated using an external calibration curve based on these standards. Each acid was expressed
as a molar percentage of the sum of SCFAs and lactic acid (TA).
2.5. Fecal DNA Extraction, Sequencing, and Taxonomic Annotation
Microbial DNA from the inner part of the stool was extracted from 150 mg of starting material
using a Fecal DNA MiniPrep kit (Zymo Research; Irvine, CA, USA), following the manufacturer’s
instruction, including a bead-beating step. DNA concentration was measured with a QubitTM 3
Fluorometer (Thermo Scientific; Waltham, MA, USA). The DNA was fragmented, and the 16S rRNA of
V3 and V4 regions amplified for library preparation, adding also the indexes for sequencing, using
a Nextera DNA Library Prep kit (Illumina; San Diego, CA, USA), with the primers suggested by
Klindworth et al. (2016) [18]. The amplicons were sequenced with a MiSeq (Illumina; San Diego, CA,
USA) in 2 × 300 paired-end mode.
The Quantitative Insights Into Microbial Ecology (QIIME 2) [19] was used to process the raw
sequences, which were uploaded to the NCBI Sequence Read Archive (BioProject ID PRJNA611632).
After demultiplexing, reads passing with Phred score ≥30 were annotated for 16S rRNA against
the Greengenes database (version gg.13_8.otus.tar.gz), with 99% identify with reference sequences.
Chimeras were also detected and then filtered from the reads, and the remaining sequences were
clustered into operational taxonomic units (OTUs) by using an open reference approach in QIIME 2.
2.6. Statistical Analysis
Between samples, the minimum number of reads count was 10,578, and average reads were
36,395 ± 11,284 and 31,287 ± 16,035 for AD and HD groups, respectively (p > 0.05). The 16S rRNA
annotated sequences were then normalized to % abundance profiles for each sample and each
taxonomic level, already known as relative abundance (RA). Taxa with RA lower than 10% were
excluded from the statistical analysis [5–20].
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Before statistical analysis, normality of distribution of the independent variables (SCFAs, lactic
acid, and hematological parameters) was checked with the non-parametric Kolmogorov–Smirnoff
test. When data were not normally distributed, a natural logarithmic transformation was used. Data
were then rechecked and resulted normally distributed. The linear mixed model was used to analyze
all these variables. The model included the fixed effect of time of sampling (2 levels, T0 and T45),
status (2 levels AD, HD), and the interaction of time of sampling with status, with the subject (dog) as
random factor repeated over the time of sampling. Bonferroni multiple testing correction was used as
a significance test. For the microbiome, Shannon and Evenness diversity indices were calculated at the
family and genus levels [17]. Beta diversity was assessed with the Brian Curtis dissimilarity matrix
and visualized using principal coordinate analysis (PCoA) plot. Analysis of similarity (ANOSIM) was
performed with the ‘Vegan’ package in R (Version 3.2.1) to test whether the microbiome significantly
differed between AD and HD at T0 and T45. All these analyses were performed with XLSTAT [21].
A linear discriminant analysis (LDA) effect size (LEfSe) was applied to detect taxa that differed between
diseased and healthy groups at T0 and T45 [22].
3. Results
Statistical analyses of plasma biochemistry results are depicted in Table 1. C-reactive protein
(CRP), urea, albumin, and lipase were significantly higher in AD (p < 0.05) in comparison to HD.
Creatine showed an increase with time of sampling (p < 0.05) in both dog groups, while for total
bilirubin, a negative variation at T45 compared to T0 (p < 0.05) was registered. Besides, this latter
parameter was higher in HD than AD (0.19 and 0.16, respectively; p < 0.05). Cholesterol underwent
positive variation for the effect of time and was higher in AD than in HD (p < 0.05). There was a
significant increase in alanine transaminase (ALT/GTP) in AD (p < 0.05), but it decreased with time
(p < 0.001), while for aspartate transaminase (AST/GOT), a decrease from T0 to T45 was reported
(p < 0.001). Alkaline phosphatase (ALP) significantly decreased from T0 to T45 (p < 0.05), being lower
in HD, similar to the creatine kinase (CK) (p < 0.05). Gamma-glutamyl transferase (GGT) was higher at
T45 (p < 0.05) compared to T0. Regarding the mineral concentrations in plasma, the analysis showed a
slight increment of Ca and Cl for the effect of time (p < 0.001), while K and Mg were statistically higher
in HD than AD (p < 0.05). Inorganic P registered a variation for the interaction time X status (p < 0.05).
Na increased from T0 to T45 (p < 0.001), being significantly higher in HD (p < 0.05). Finally, the plasma
concentrations of vitamin B12 and folates were significantly higher in AD (p < 0.05) in comparison
to HD.
Table 1. Mean concentrations of the parameters determined by blood biochemistry in healthy (HD)
and diseased (AD) dogs at the beginning of the study (T0) and after 45 days (T45).
Item Unit
T0 T45 SEM Effects
AD HD AD HD Time Status T x S
Glucose mg/dL 93.14 94.23 92.86 95.77 1.20 NS NS NS
Fructosamine umol/L 204.93 191.23 215.21 219.77 5.14 NS NS NS
Urea mg/dL 35.50 36.28 36.71 35.08 1.38 NS * NS
Creatine mg/dL 1.28 1.13 1.42 1.36 0.04 * NS NS
Total bilirubin mg/dL 0.20 0.26 0.16 0.19 0.01 * * NS
Total proteins g/dL 6.84 6.85 6.91 6.92 0.05 NS NS NS
Albumin g/dL 3.04 2.98 3.01 2.91 0.04 NS * NS
Globulin g/dL 3.81 3.87 3.90 4.02 0.06 NS NS NS
Albumin/Globulin g/dL 0.81 0.78 0.77 0.74 0.02 NS NS NS
Cholesterol mg/dL 238.29 228.31 266.57 242.15 7.07 NS NS *
Triglycerides mg/dL 63.29 68.23 53.14 58.46 3.28 NS NS NS
Lipase u/L 118.43 86.92 88.57 64.23 8.39 NS * NS
C-Reactive Protein mg/dL 0.41 0.15 0.33 0.12 0.03 NS * NS
α-Amylase u/L 819.71 771.77 727.07 767.92 34.51 NS NS NS
AST (GOT) u/L 30.79 32.23 21.64 25.08 0.99 ** NS NS
ALT (GPT) u/L 56.29 29.31 31.86 22.46 2.69 ** * *
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Table 1. Cont.
Item Unit
T0 T45 SEM Effects
AD HD AD HD Time Status T x S
ALP u/L 59.57 69.62 52.14 46.69 3.15 * NS NS
GGT u/L 6.93 6.46 7.07 7.46 0.20 * NS *
CK u/L 102.43 158.92 90.29 97.69 8.82 NS NS NS
LDH u/L 42.36 67.37 52.50 59.46 6.28 NS NS NS
Cholinesterase mg/dL 6000.50 6232.00 6301.64 6472.95 231.02 NS NS NS
Ca mg/dL 10.14 10.02 10.91 10.44 0.10 ** NS NS
P-in mg/dL 3.49 5.03 3.89 3.98 0.16 NS NS *
Mg mg/dL 2.25 2.32 2.18 2.39 0.03 NS * NS
Fe µg/dL 154.79 175.69 148.07 188.54 7.70 NS NS NS
Cl mEq/L 109.64 109.11 111.07 110.53 0.52 * NS NS
K mEq/L 4.45 4.76 4.53 4.91 0.06 NS * NS
Na mEq/L 146.86 149.20 148.86 149.92 0.41 ** * NS
TLI ng/mL 37.74 26.61 48.62 38.25 5.37 NS NS NS
Folates ug/L 10.74 11.63 11.52 12.17 0.64 NS * NS
Vitamin B12 pg/mL 326.64 500.69 360.79 451.46 29.07 NS * NS
SEM: standard error of the means; AST (GOT): aspartate transaminase; ALT (GPT): alanine transaminase; ALP:
alkaline phosphatase; GGT: gamma-glutamyl transferase; CK: creatinine kinase; LDH: lactate dehydrogenase; P-in:
inorganic P; TLI: trypsin-like immunoreactivity. * p < 0.05; ** p < 0.001; NS: not significant.
The concentrations and the molar proportion (%) of the SCFAs and lactic acid are reported in
Supplementary Table S2. The molar concentrations of SCFAs and TA were not significant for any effect.
Lactate and isovalerate showed a numerical increase in diseased subjects. The molar proportion of
acetate showed a decrease (p < 0.05) at T45 compared to T0 in all the groups, while the molar proportion
of butyrate was higher in AD in comparison to HD (7.7% vs. 7.0%, p < 0.05). No significant variation
was registered for the other SCFAs.
Shannon index of diversity (H’) and Evenness index (J’) of the fecal microbiome significantly
differed between AD and HD at the family level but not at the genus level (Figure 1).
The principal coordinate analyses (PCoA) was used to visualize beta diversity (Figure 2) between
groups. The ANOSIM computed for the two times of sampling was significantly different at the family
level (p < 0.01) between the two groups of dogs.
The differences in taxonomical terms between the two groups are depicted in Figure 3. The
bacterial taxa that were significantly increased in HD dogs were the families Paraprevotellaceae,
Porphyromonadaceae, and Mogibacteriaceae and the genera Parabacteroides, Phascolarctobacterium,
and p_75_a5. Even the family Peptococcaceae and its genus Peptococcus together with the family
Succinivibrionaceae and its genus Anaerobiospirillum were significantly higher in HD. Indeed, the genus
Megamonas showed a significantly higher relative abundance in AD.
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Figure 1. Shannon (H’) and Evenness (J’) indexes of diversity in arthritic (AD) and healthy (HD) dogs.
Panel (A) shows mean values at the family level (means were significantly different for p < 0.05 between
AD and HD groups). Panel (B) shows mean values at the genus level (means were not significantly
different between AD and HD groups). Shannon index was calculated according to the equation H’ =
−sum (Pi × ln Pi), where Pi = frequency of every taxon within the sample. The evenness index was
calculated as J’ = H’/ln S, where S = total number of taxa within each sample.
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Figure 2. Principal coordinate (PCoA) plot representing the beta diversity of the microbial community
among dogs’ health status at family (A) and genus (B) level. PCoA was calculated using the Brain
Curtis dissimilarity matrix. Dots in red represent arthritic dogs (AD), and dots in blue represent the
healthy dogs (HD). The analysis of similarity (ANOSIM) was significant at the family level for p < 0.01.
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Figure 3. Bacterial taxa were significantly more abundant in the feces of healthy (HD) and arthritic
dogs (AD). The cladogram (A) highlights impactful communities in individuals from each status, and
(B) shows the score of the linear discriminant analysis (LDA, significant threshold >2).
4. Discussion
Osteoarthritis is a multifactorial and slowly progressive disease, resulting in a difficult early
diagnosis through radiography or plasma biochemical analysis [23]. Different studies have revealed
the relationship between cardiovascular disease, obesity, type 2 diabetes, and osteoarthritis, focusing
on the role of the metabolic syndrome in provoking joint and bone damage [24,25].
Biochemical analyses of plasma are a suitable marker of inflammation (Table 1). CRP is a parameter
of the acute phase of inflammation, and its detection in plasma could be useful in carrying information
for the discrimination between suppurative arthritis and osteoarthritis in dogs, as demonstrated by
Hillström et al. (2016) [26]. Rafiqul et al. (2006) [23] studied CRP concentration in dogs affected
by stifle osteoarthritis and observed an increased concentration of CRP after 3, 6, and 9 months of
experimental study. More recently, even Hindenberg et al. (2020) [27] focused on the significance of the
concentration of high CRP (>1 mg/dL) in dogs. Classifying dogs in categories based on etiology and
organ system affection, they found that the prevalent etiology was the inflammation (59%), in which
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51% was infectious, and interestingly, of this 51%, the 38% had a bacterial origin. Instead, relying on
the affected organs, aside from multiple organs and trauma (39 and 20%, respectively), they detected
an incidence of 14% for the gastrointestinal tract and 7% of the musculoskeletal system. Here, the AD
group presented significantly higher values of CRP with respect to HD, and this could support that
this parameter can be a marker of the arthritic process, including that of bacterial origin.
In this study, cholesterol significantly increased in AD at T45 when compared to HD, suggesting
that an inflammation process was in the act. Rafiqul et al. (2006) [23] registered an increase in plasma
cholesterol in dogs affected by stifle osteoarthritis. Cholesterol concentration has been reported to be
an important biomarker of inflammation in obese dogs [28], mainly due to excess in the production of
adipokines, which affects insulin resistance, and to the adipocyte secretions of inflammatory mediators,
such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and others, which contribute to systemic
inflammation. Chronic low-grade systemic inflammation plays a fundamental role in the onset
of several diseases in humans, such as coronary artery disease, insulin resistance, and metabolic
syndrome [29–31]. A study on humans conducted by Farnaghi et al. (2017) [32] discovered that
synovial fluid contains a low concentration of cholesterol compared to plasma levels, while the synovial
fluid of osteoarthritic subjects has a higher amount of cholesterol and cholesterol crystals than healthy
individuals. Furthermore, high plasma cholesterol can be found in overweight and obese dogs [33].
Since a correlation between gut dysbiosis and obesity/overweight has been reported [33,34], it is
acceptable to assume that obesity conditions may be also related to other conditions of systemic
inflammation, as arthritis.
ALP is a nonspecific phosphomonoesterase that hydrolyzes phosphate monoesters, and it is found
attached to the plasma membrane, where extensive transport takes place [35]. ALP localized in the
plasma membrane of the osteoblastic cells seems to have a specific role in bone mineralization [36],
even if more pieces of evidence are needed to be found. ALP is found in many tissues, but especially in
bones, liver, bile ducts, and in the gut epithelium, and an increase of this enzyme in plasma constitutes
a biochemical marker of disease of these tissues; ALP is also used, together with epidemiologic,
clinical, laboratory, and radiographic findings, to characterize polyarthritis in dogs [37]. In this study,
we detected a significant decrease in ALP at T45, both in AD and more evidently in HD groups.
Musco et al. (2019) [38], in a dietary intervention study on dogs affected by osteoarthritis, found lower
ALP activity in the group receiving the prebiotic supplement than in sick dogs. In addition, mucosal
expression, intestinal activity, and fecal concentration of ALP have been discovered to be lower in dogs
with chronic inflammatory enteropathies [39], advising the use of this enzyme as a biomarker, also for
enteropathies in dogs.
Cobalamin (vitamin B12) and folates (vitamin B9) detected in serum represent reliable functional
biomarkers of intestinal permeability and malabsorption in dogs [40,41]. Cobalamin is absorbed only
in the ileum, and its lower concentration is often associated with chronic intestinal pathologies in
dogs [42–44], presumably manifested as small intestine malabsorption, secondary small intestine
dysbiosis (extensive utilization of vitamin B12 by commensal bacteria), or both. Hypocobalaminemia
is associated with lower serum albumin concentration [42] in the case of a gastrointestinal protein loss
due to chronic intestinal inflammation [45,46]. However, in the present study, albumin concentration
was higher in the AD group, although vitamin B12 was decreased; hence, it is not possible to attribute
these changes to protein-losing enteropathy.
Folates are firstly absorbed in the duodenum and proximal jejunum as folate glutamate through
B9 carriers, and they are principally produced by Bifidobacteria and Lactobacillus strains [47]. According
to Heilmann et al. (2018) [44], hypofolatemia can derive from chronic malabsorption in the proximal
small intestine of dogs, but at the same time, an increase or a normal concentration of vitamin B9 can
be a symptom of a secondary small intestine dysbiosis, in which a high production of folates is made
by resident microbiota or hypocobalaminemia [48]. Even Xu et al. (2016) [49] registered a decrease in
serum folate in dogs affected by inflammatory bowel disease (IBD), together with lower cobalamin
concentration. In this study, these parameters were sharply higher in HD group than in the AD group,
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both at T0 and T45, suggesting a healthier and more functional gut microbiome in the former dogs,
able to supply the required amount of vitamins the organism needs. It is already evident the capacity
of the gut population to synthesize the necessary elements to sustain the organism’s homeostasis
through the production of vitamins of the B group and secondary metabolites, such as SCFAs and lactic
acid [50]. Dysregulation of this mechanism could compromise the mutualistic relationship among gut
microbiome and host.
In regard to SCFAs, no particular variations were detected between the two groups, except for
the molar proportion of butyrate that showed an increase in the AD group (Supplementary Table S2).
The lack of substantial differences between the two groups in terms of SCFAs could be consequent
to the rapid absorption of these metabolites, leaving a small but detectable concentration in feces.
As already known, dogs do not utilize SCFAs as the principal source of energy, as ruminants do, but
the dissimilarities, at least, indicate a variation in nutrient metabolism associated with a modification
of gut microbiome.
Acetate, propionate, and butyrate exert beneficial effects on the homeostasis of metabolic functions
since they have anti-inflammatory properties by controlling the development and modulating the
immune system [51]. Besides the fact that butyrate is apported with the diet, this acid is mainly
produced by the fermentation of the dietary fiber by Clostridial cluster IV and XIVa [52] in the gut
lumen. Moreover, it acts through G protein-coupled receptor (GPCRs) pathway or by reducing
histone deacetylases (HDACs) [53], involving the recruitment of macrophages and DCs to facilitate
differentiation of T reg cells and immune-regulatory IL-10 [54]. Butyrate also supplies energy to the
colonocytes, which means that a significant proportion of microbial-released butyrate is rapidly taken
up and consumed locally [55], regulate host cell responses, and, for this reason, is considered to exert
health-promoting effects on the colon [56]. Unexpectedly, our data indicated that the molar proportion
of butyrate was higher in AD, even though the mean values of butyrate proportion were numerically
close between the two groups. This could be explained by the fact that arthritic dogs possess many
butyrate producers, such as Megamonas genus, as registered in the study by Sandri et al. (2017) [17],
and/or a relatively few bacterial butyrate-consumers. Moreover, since butyrate can even be synthesized
from acetate and lactate from the interactions with the microbial ecosystem [57,58], the increased
butyrate in AD is likely due to this over synthesizing activity.
The reduction of alpha diversity indices (Figure 1), at least at the family taxonomic level, indicated
that a dysbiosis probably occurred in the AD group, as supported by Minamoto et al. (2015) [59].
Furthermore, we also found differences in the relative abundances of bacterial taxa between AD and
HD (Supplementary Tables S3 and S4) and beta diversity at the family level (Figure 2), suggesting a
link between the microbiome and joint inflammation, even though no variation was observed at the
genus level.
Although the markers of the leaky gut were not analyzed, the variation of the gut microbial
community and the decrease of serum cobalamin and folates supported the hypothesis that a dysbiosis
occurred. Several studies have investigated the modulation in gastrointestinal bacterial patterns and
gut functional status in patients with arthritis. Ad exemplum, the study conducted by Muniz Pedrogo
et al. (2019) [60] on humans reported an increased abundance of Clostridiaceae in both rheumatoid
arthritis and IBD-associated arthropathy. Instead, Coulson et al. (2013) [61] found a high number of
Bacteroides, Eubacterium (Collinsella aerofaciens), Lactobacillus, Bifidobacterium, Clostridium, Coliforms
(Escherichia coli, Klebsiella pneumoniae), Enterococcus, Streptococcus, Staphylococcus, and Prevotella in
patients with knee osteoarthritis. Wolfe et al. (2000) [62] reported that patients diagnosed with
musculoskeletal diseases registered also common predispositions to dyspepsia, nausea, abdominal
bloating, and irregular bowel habits. The interference of gut microbiota with bone metabolism has
been postulated also in mice, in which a reduction of bone loss associated with ovariectomy has been
reported after probiotic administration [63,64]. Even Mc Cabe et al. (2013) [65] found that the use of
probiotic on male mice decreased intestinal inflammation and increased bone density. Another study
on mice, supporting the relation among microbiome and arthritis, found that members of the genus
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Prevotella might influence bone loss by regulating the levels of SCFAs that mediate osteoclastogenesis in
the host [66]. The differences of relative abundance of taxa in AD and HD groups found in tour study
do not overlap with the previous researches, but it is legitimate to consider that a strict comparison of
dogs’ microbiome with humans and mice microbiome is not feasible due to the peculiar anatomy and
physiology of these species, and then the observed differences were expected.
LEfSe analysis (Figure 3) revealed deep differences between the relative abundances of some taxa.
Interestingly, we found a greater abundance of the genus Megamonas in AD, while the other genera
were higher in HD. Other than butyrate, Megamonas is known to produce propionate, which has been
shown to possess anti-inflammatory properties, and, additionally, this genus affects the metabolic rate
of the host organism [67]. Here, the relative abundance of Megamonas in AD was 2-fold higher than
that of the HD group and vice versa, while Phascolarctobacterium was 2-fold lower. It seemed that a
shift from Megamonas with the Phascolarctobacterium occurred in AD and HD microbiome since these
taxa belong to the same family of Veilloneaceae. Similar results have also been observed in human
studies [68,69], suggesting that these two genera occupy the same ecological niche and compete for the
same substrates. On the other hand, it should be considered that data refer to relative abundances,
meaning that the increase of Megamonas might be due to a decrease of other genera and so do not
necessarily reflect a higher amount of this genus in the microbial population of arthritic dogs.
We also detected, in HD group, a higher abundance of bacterial members of the Clostridiales
order (Mogibacteriaceae, Peptococcaceae along with Peptococcus genus and Phascolarctobacterium genus)
and in Erysipelotricaceae (p_75_a5 genus), sharing the same Firmicutes phylum. Clostridiales plays a
crucial role in preventing leaky gut syndrome, which occurs when gut barrier permeability is altered,
prompting excessive inflammation [70]. Similar results were found in a study on dogs conducted
by Minamoto et al. (2015) [59], in which Erysipelotricaceae, Clostridiales, and Bacteroidetes were
underrepresented in dogs with IBD. Even members of the Bacteroidales order (Paraprevotellaceae,
Porphyromonadaceae, and genus Parabacteroides) showed a higher abundance in HD. On the contrary,
Omori et al. (2017) [71] found a great abundance of Paraprevotellaceae and Porphyromonas genus in
dogs affected by IBD. The presence of the Parabacteroides genus in humans is thought to help to prevent
the invasion and colonization of pathogens by secreting bacteriocins that are toxic to other strains of
bacteria [72]. Individuals with IBD often lack a population of Parabacteroides in their gut, suggesting that
this genus also helps protect against excessive inflammation [72]. Unexpectedly, Aeromonadales—the
relative belonging family Succinivibionaceae and the relative genus Anaerobiumspirillum—were higher
in healthy dogs. These bacteria belong to the Proteobacteria phylum, which has been associated with
IBD [59–73], even if Anaerobiospirillum is commonly found in feces of healthy dogs [74].
Definitively, the lesson to get from these results is that gut microbiome is a complex ecosystem,
and thus the variation in the composition of the microbiome as a whole, rather than to the variation of
the single taxon, can better depict the effect of an inferred factor in gut-host microbiota interaction.
The modulation of the gut microbiome by arthritis risk factors (e.g., diet, obesity, age, physical
exercise, sex, genetic factors, and immunity activation) could alter the intestinal thigh junctions,
allowing the crossing of the local bacteria by the DCs and macrophages, which eventually can reach
tissue or organs through the bloodstream, causing an inflammatory response in the host [6]. It can be
argued that the gut is a source of these microorganisms because altered gut permeability has been
observed in individuals with arthritis [75,76]; therefore, some living bacteria could be transferred from
the gut to the joints through the circulatory or lymphatic system [77]. The existence of this axis in dogs
deserves further investigations to be better understood.
5. Conclusions
The gut microbiome is strictly related to several forms of pathologies. In the present study, we
analyzed the variation of the gut microbial community in arthritic dogs, and the results obtained
suggested that it might influence the degeneration of joints and bones through the propagation of
systemic inflammation. Despite our findings on bacterial taxa of dog microbiome were not similar to
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those detected in other studies, we hypothesized that a large inter-individual variability among dogs
exists and that different bacterial strains could contribute in a unique way to modify the inflammatory
status of the subjects. Hence, it is not possible to attribute a beneficial or harmful role to a single
taxon in arthritic disease but is likely that a variation of the total genera composing microbiome could
reshape the entire physiology of the host.
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